Skip to main content

Table 4 Multivariable logistic analyses of potential benefit factors for pathologic response in terms of tumor-related analysis

From: Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases

Variable

OR (95% CI)

P valueb

Age (> 65 vs. ≤ 65 years)

0.84 (0.30–2.35)

0.743

Primary tumor site (left vs. right)

0.44 (0.21–0.92)

0.030

pN category (pN1-2 vs. pN0)

1.04 (0.56–1.91)

0.903

CEA decline (yes vs. no)a

0.48 (0.24–0.94)

0.032

Metastases presentation (metachronous vs. synchronous)

0.72 (0.30–1.74)

0.462

Size of metastases (< 2.5 vs. ≥ 2.5 cm)

0.50 (0.27–0.92)

0.025

Resection status (R1–2 vs. R0)

1.09 (0.56–2.13)

0.794

Preoperative chemotherapy backbone (CT with Bev vs. CT only)

0.29 (0.10–0.83)

0.021

Preoperative chemotherapy backbone (CT with Cet vs. CT only)

1.79 (0.86–3.73)

0.120

Duration of preoperative chemotherapy (long vs. short)

0.28 (0.14–0.53)

< 0.001

  1. CEA carcinoembryonic antigen, CT chemotherapy, Bev bevacizumab, Cet cetuximab
  2. a Because initial CEA levels were unavailable, 30 of 159 patients (85 of 380 available tumors) were not evaluable for CEA variations
  3. b P < 0.05 was emphasized in italics